Month: January 2024

Release – Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

Posted on by aweinsoff@channelchek.com

Research News and Market Data on UNCY

January 23, 2024 7:03am EST Download as PDF

– Topline Data from OLC Pivotal Trial Expected in Q2 2024 –
– OLC will target the multibillion-dollar hyperphosphatemia market –

LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today issued a letter to shareholders.

Dear Shareholders:

As I sit down to write this letter, I am filled with a profound sense of gratitude and excitement, energized for the year ahead. I remain as confident as ever that the work we’re doing at Unicycive will change the treatment paradigm in kidney disease and leave a lasting impact for patients, physicians, and for you, our shareholders.

When I founded Unicycive in 2016 I knew the journey we were embarking on was ambitious—to offer hope to the millions of patients suffering from chronic kidney diseases who continue to go underserved. Thanks to your unwavering support and the steadfast commitment of our small but mighty team, I am constantly amazed at how we’re able to tackle obstacles head on, solve problems efficiently, and continue to move closer to our goal.

In this letter, I am pleased to recap for you another year of great accomplishments. We’ve made significant advancements in our clinical programs which will propel us to new heights in 2024.

Addressing a Critical Need

Today, dialysis patients experience an excessive pill burden that is among the highest across various chronic disease states including HIV/AIDS, diabetes mellitus, and congestive heart failure. Phosphate binders to treat hyperphosphatemia account for half of the problem.1

Importantly, uncontrolled hyperphosphatemia is strongly associated with increased hospitalization and mortality.2

Our lead program, Oxylanthanum Carbonate, or OLC, is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology with two key advantages. First, only three tablets are required per day (versus as many as 12) and each are meaningfully smaller in size compared to the currently approved phosphate binders. Second, the tablets are swallowed whole with water and not chewed, making it easier for patients to take.3

The novel characteristics of OLC show its potential to be a best-in-class product to treat hyperphosphatemia by reducing the pill burden volume by more than 4-fold compared to the most prescribed phosphate binder.

During 2023 we made significant progress with OLC under the FDA’s 505(b)(2) regulatory pathway which allows us to reference the already approved drug, lanthanum carbonate (Fosrenol®4) to streamline our submission package. As reported in December 2022, OLC was evaluated in a previous bioequivalence study that measured efficacy in healthy volunteers (n=80) in which OLC has found to be equivalent to the reference drug, Fosrenol.

Last year, we gained alignment with the FDA on the overall data package required (preclinical, clinical and CMC) to file a New Drug Application (NDA). The Agency agreed with our proposed clinical study design including sample size, duration of treatment, and primary endpoint of the study. Last month, we initiated the pivotal clinical trial (NCT06218290) to evaluate the tolerability of OLC in chronic kidney disease (CKD) patients on dialysis (n=60) and expect to report topline data in the second quarter of this year. This is the last major component to complete our data package to file an NDA with the FDA, which we intend to submit mid-year.

If approved, OLC will target the multibillion-dollar hyperphosphatemia market and will be a new potential therapy for physicians to administer to their patients.

Strong Scientific Leadership with OLC

This year we continued to publish scientific data on OLC at national and international conferences. We presented five posters on OLC at conferences including at the National Kidney Foundation (NKF), International Society of Nephrology (ISN) and European Renal Association (ERA).

We also published two manuscripts on OLC in peer reviewed journals. The American Journal of Nephrology publication highlighted the phosphate binding capacity of OLC showing that OLC had the lowest daily phosphate binder dose volume and the lowest volume required to bind one gram of phosphate compared to five other commercially available phosphate binders.

Increasing Market Awareness

A top priority for us in 2023 was growing market awareness of OLC’s potential best-in-class product profile. We conducted live and virtual advisory board meetings with some of the country’s most influential nephrologists. Also, for the first time, Unicycive exhibited at the American Society of Nephrology Kidney Week, the world’s premier nephrology conference where we showcased the high unmet need in the management of hyperphosphatemia and the urgent need for new therapies like OLC (https://www.lesspillburden.com). We are encouraged by the overwhelmingly positive reception to the OLC story and are planning continued market-shaping activities for 2024.

Portfolio Expansion

In addition to OLC, we continue to advance our second compound UNI-494 for the treatment of acute kidney injury and chronic kidney disease. UNI-494 is a novel nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator. Mitochondrial dysfunction plays a critical role in the progression of acute kidney injury and chronic kidney disease. UNI-494 has a novel mechanism of action that restores mitochondrial function and may be beneficial for the treatment of several diseases including kidney disease. The asset is currently in a Phase 1 dose-ranging safety study in healthy volunteers in the United Kingdom that is expected to complete this year.

UNI-494 is protected by issued patents in the U.S. and Europe and a wide range of patent applications worldwide.

Looking Ahead

We believe 2024 will be a transformational year for Unicycive. We will report out our pivotal data for OLC next quarter and plan to complete our data package and submit an NDA mid-year. We continue to work closely with the medical community to publish data on our programs and plan for future commercialization of OLC.

As a company, all of our stakeholders are vital to our success. I would like to express my deep appreciation to the physician investigators, study participants, and especially to our dedicated Unicycive employees. The progress we have made demonstrates what’s possible when we believe in the work we are doing and come together to make a meaningful difference.

Thank you for your support,

Shalabh Gupta, MD, Chief Executive Officer of Unicycive

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn and YouTube.

Forward-looking statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

References:
1 Chiu YW, et al. Clin J Am Soc Nephrol. 2009
2 Block GA, et al. J Am Soc Nephrol. 2004
3 Dosing information: www.accessdata.fda.gov
4 Fosrenol® is a registered trademark of Shire International Licensing BV.

Investor Contact:

ir@unicycive.com
(650) 543-5470

SOURCE: Unicycive Therapeutics, Inc.

Released January 23, 2024

Release – SelectQuote to Release Fiscal Second Quarter 2024 Earnings on February 7

Posted on by aweinsoff@channelchek.com

Research News and Market Data on SLQT

January 23, 2024

OVERLAND PARK, Kan.–(BUSINESS WIRE)– SelectQuote, Inc. (NYSE: SLQT), a leading distributor of Medicare insurance policies and owner of an emerging Healthcare Services platform, announced today that it will release its fiscal second quarter 2024 financial results prior to market open on Wednesday, February 7, 2024. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (February 7, 2024) at 8:30 am ET to discuss the results.

To register for this conference call, please use this link: https://www.netroadshow.com/events/login?show=3bad4d79&confId=59966

After registering, a confirmation will be sent via email, including dial in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering a day in advance or at minimum 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx or via this link.

About SelectQuote:

Founded in 1985, SelectQuote (NYSE: SLQT) provides solutions that help consumers protect their most valuable assets: their families, health, and property. The company pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote’s success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads.

With an ecosystem offering high touchpoints for consumers across insurance, medicare, pharmacy, and value-based care, the company now has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, and Population Health which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

Investor Relations:
Sloan Bohlen
877-678-4083
investorrelations@selectquote.com

Media:
Matt Gunter
913-653-4375
matt.gunter@selectquote.com

Source: SelectQuote, Inc.

Release – YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024

Posted on by aweinsoff@channelchek.com

Research News and Market Data on YS

GAITHERSBURG, Md., Jan. 22, 2024 /PRNewswire/ — YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma”) along with its subsidiaries (“YS Group” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its unaudited consolidated financial results for the first half of the fiscal year ended March 31, 2024 (the “first half of fiscal year 2024”).

Dr. David Shao, Director, President, and CEO of the Company, commented, “During the first half of fiscal year 2024, though we continued to experience the lingering impact of inventory issues from previous COVID-related disruptions at our YSJA rabies vaccine manufacturing facilities, we executed various operational enhancements to overcome past setbacks. By improving our raw material supply, refining our inventory management, and optimizing the production throughput, our vaccine production operation has returned to normal, and our inventory situation is improving. With higher production throughput and a healthier inventory level of finished products, we expect that the second quarter of our fiscal year 2024 will be the last to be impacted by the previously incurred production delays. Meanwhile, we expect YSJA rabies vaccine revenues in the third quarter, ended December 31, 2023, to increase approximately 50% sequentially from the second quarter, ended September 30, 2023. Our promising array of product candidates are advancing in the development, and we are optimistic about the potential of our PIKA rabies vaccine to provide us with an important new advantage.”

“At the same time, we are fortifying our corporate governance and streamlining our decision-making process to bolster our foundation for long-term and sustainable growth,” Dr. Shao continued. “We have taken steps to diversify our Board composition with the addition of global pharmaceutical industry leadership and US capital market expertise to our company, a move which has thus far been lauded by our shareholders. Under the stewardship of our board of directors, we will continue to innovate and capitalize on resurgent demand from the market.”

Ms. Brenda Wu, CFO of the Company, added, “For the first half of fiscal year 2024, our revenues were RMB273.1 million, mainly due to COVID-related disruptions affecting raw material supply chains, manufacturing operations, and production output at our YSJA rabies vaccine production facilities. Our gross profit for the period was RMB220.9 million, and we expanded our gross profit margin by 4.3 percentage points to 80.9%. Our cash and cash equivalents totaled RMB259.9 million at the end of the period. Looking ahead, we will continue to strategically enhance our business and capitalize on growth opportunities as we strive to deliver long-term value for our shareholders.”

Business Updates

YSJA™ Rabies Vaccine

YS Biopharma’s marketed vaccine product, YSJA™ rabies vaccine, was the first aluminum-free lyophilized rabies vaccine launched in China. Since the Company commenced production at its current GMP-compliant facilities in February 2020, and, since it commenced the product’s commercialization in late 2020, market intake of the Company’s YSJA rabies vaccine has been consistent and strong. As of September 30, 2023, YS Biopharma had sold more than 23.5 million doses of YSJA™ rabies vaccines to approximately 1,718 Chinese Center(s) for Disease Control and Prevention (“CDC”) customers, which represents over 59.6% of CDC customers in China since October 2020.

Clinical Pipeline

YS Biopharma continues to advance its portfolio of innovative product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001, and PIKA YS-HBV-002.

PIKA Rabies Vaccine

  • On October 31, 2023, the Company announced that it had completed the enrollment of subjects in its Phase III clinical trial of the PIKA rabies vaccine. The trial includes a total of 4,500 participants from Pakistan and the Philippines, and will assess the safety, immunogenicity, and lot-to-lot consistency of the PIKA rabies vaccine. Interim results are expected in the first half of 2024.

PIKA Recombinant COVID-19 Vaccine

  • In March 2023, the Company reported positive interim safety and immunogenicity data for the PIKA recombinant COVID-19 vaccine from Phase II of the Phase II/III clinical studies which were completed in the Philippines and the UAE. The safety and efficacy of the Company’s PIKA adjuvant technology was validated in the Phase II/III trial, which involved roughly 6,000 participants. The Company anticipates that the results from the Phase III clinical trials will be released during the first half of 2024.
  • The Company will continue to monitor the evolving global situation surrounding COVID-19, and will utilize appropriate commercialization strategies for the PIKA recombinant COVID-19 vaccine accordingly.

PIKA YS-ON-001

  • PIKA YS-ON-001 is designed as an immunological therapeutical agent against cancers. The Company has completed the Phase I clinical trial of PIKA YS-ON-001 in China.

PIKA YS-HBV-002

  • On September 15, 2023, the Company announced that the United States Patent and Trademark Office had issued it a patent covering its PIKA YS-HBV-002, an immunotherapeutic vaccine designed to treat patients suffering from chronic hepatitis B virus (HBV) infection.
  • The Company expects to complete an Investigational New Drug (IND) application and commence the clinical development of PIKA YS-HBV-002 as a novel immunotherapy for the treatment of chronic HBV infection in 2024.

First Half of Fiscal Year 2024 Financial Results

Total Revenues

Total revenues were RMB273.1 million (US$38.0 million) in the first half of fiscal year 2024, compared to RMB399.5 million in the same period of fiscal year 2023, representing a decrease of 31.6%. This was primarily due to COVID-related disruptions affecting the Company’s manufacturing operations and production, which reduced batch approvals and doses available for sale; offset by the increases in product price by approximately RMB3.0 per dose.

Gross Profit

Gross profit was RMB220.9 million (US$30.8 million), representing an 80.9% gross margin, compared to RMB305.8 million, or a 76.5% gross margin, in the same period of fiscal year 2023.

Selling and Marketing Expenses

Selling and marketing expenses in the first half of fiscal year 2024 were RMB157.7 million (US$22.0 million), compared to RMB150.2 million in the same period of fiscal year 2023. This increase was primarily attributable to an increase in promotional and marketing services fees as the Company continued to promote its YSJA rabies vaccine.  

General and Administrative Expenses

General and administrative expenses in the first half of fiscal year 2024 were RMB67.6 million (US$9.4 million), compared to RMB49.6 million in the same period of fiscal 2023. This change was primarily attributable to increases in 1) professional service fees, due to the Company’s status as a publicly-listed entity, 2) management salaries, and 3) provision for trade receivables and inventories.

Research and Development Expenses

Research and development expenses were RMB178.9 million (US$24.9 million) in the first half of fiscal year 2024, compared to RMB123.9 million in the same period of fiscal 2023. The increase was primarily driven by an increase in testing and clinical trial fees associated with the Company’s COVID-19 vaccine, PIKA rabies vaccine, and hepatitis B vaccines.

Net Loss

Net loss for the first half of fiscal year 2024 was RMB174.5 million (US$24.3 million), compared with RMB11.1 million in the same period of 2023.

Balance Sheet

As of September 30, 2023, the Company had cash and cash equivalents of RMB259.9 million (US$36.2 million), compared with RMB370.4 million as of March 31, 2023.

About YS Group 

YS Group is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. YS Biopharma operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharm.com.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.1798 to US$1.00, the exchange rate set forth in the central parity rate release of the People’s Bank of China on September 30, 2023.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of the Company, the development progress of all product candidates, the progress and results of all clinical trials, the Company’s ability to source and retain talent, and the cash position of the Company following the closing of the Business Combination. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of YS Biopharma’s management and are not predictions of actual performance.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although YS Biopharma believes that it has a reasonable basis for each forward-looking statement contained in this press release, YS Biopharma cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in the final prospectus relating to the Business Combination, and other documents filed by YS Biopharma from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

YS Biopharma cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the ability to recognize the anticipated benefits of the Business Combination, costs related to the transaction, the impact of the global COVID-19 pandemic, the risk that the transaction disrupts current plans and operations as a result of the consummation of the transaction, the outcome of any potential litigation, government or regulatory proceedings, the sales performance of the marketed vaccine product and the clinical trial development results of the product candidates of YS Biopharma, and other risks and uncertainties, including those included under the heading “Risk Factors” in the post-effective amendment No. 1 to Form F-1 filed with the SEC on August 8, 2023 which became effective on August 10, 2023, and other filings with the SEC. There may be additional risks that YS Biopharma does not presently know or that YS Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of YS Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while YS Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of YS Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, YS Biopharma does not undertake any duty to update these forward-looking statements.

Investor Relations Contact

Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-announces-unaudited-financial-results-for-the-first-half-of-fiscal-year-2024-302041147.html

SOURCE YS Biopharma Co., Ltd.

Comtech Telecommunications (CMTL) – A First Step

Posted on by cpereira@noblefcm.com


Tuesday, January 23, 2024

Comtech Telecommunications Corp. engages in the design, development, production, and marketing of products, systems, and services for advanced communications solutions in the United States and internationally. It operates in three segments: Telecommunications Transmission, Mobile Data Communications, and RF Microwave Amplifiers. The Telecommunications Transmission segment provides satellite earth station equipment and systems, over-the-horizon microwave systems, and forward error correction technology, which are used in various commercial and government applications, including backhaul of wireless and cellular traffic, broadcasting (including HDTV), IP-based communications traffic, long distance telephony, and secure defense applications. The Mobile Data Communications segment provides mobile satellite transceivers, and computers and satellite earth station network gateways and associated installation, training, and maintenance services; supplies and operates satellite packet data networks, including arranging and providing satellite capacity; and offers microsatellites and related components. The RF Microwave Amplifiers segment designs, develops, manufactures, and markets satellite earth station traveling wave tube amplifiers (TWTA) and broadband amplifiers. Its amplifiers are used in broadcast and broadband satellite communication; defense applications, such as telecommunications systems and electronic warfare systems; and commercial applications comprising oncology treatment systems, as well as to amplify signals carrying voice, video, or data for air-to-satellite-to-ground communications. The company serves satellite systems integrators, wireless and other communication service providers, broadcasters, defense contractors, military, governments, and oil companies. Comtech markets its products through independent representatives and value-added resellers. The company was founded in 1967 and is headquartered in Melville, New York.

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strategic Investment. In the first step in the ultimate refinancing of its credit facility, Comtech announced a new $45 million investment from existing investors White Hat Capital Partners and Magnetar Capital. The new investment provides Comtech with financial flexibility in its refinancing as well as supports its strategic initiatives in satellite ground station infrastructure and next generation terrestrial wireless and wireless solutions.

Details. White Hat and Magnetar purchased $45.0 million of a new series of convertible preferred stock and exchanged all outstanding shares of Comtech’s existing convertible preferred stock for shares of the new series of convertible preferred stock. The preferred stock will be convertible into shares of Comtech common stock at a conversion price of $7.99 per share; carries a 9.00% dividend, payable in kind, or a 7.75% dividend, payable in cash, at Comtech’s election; and contains an optional redemption date of October 31, 2028. We expect additional details to be included in an 8-k filing in the next couple of days.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Rotating Into Mining: The Overlooked Opportunity in Natural Resources

Posted on by slightbourne@noblecapitalmarkets.com

In the investing world, money often rotates between different sectors over time. After a long period of technology stocks dominating, we may now be entering a new cycle where mining and natural resource stocks start to outperform other industries and sectors. There are several compelling reasons mining could be the next big thing for investors.

First, demand is soaring for the critical minerals and metals used in electric vehicles, batteries, and clean energy. Metals like lithium, nickel, cobalt, and copper are essential for manufacturing electric car batteries, solar panels, wind turbines, and other green technologies. With many countries pushing for faster adoption of EVs and renewable power, demand for these key minerals is skyrocketing. Major automakers have announced ambitious electric vehicle plans, which requires secure access to raw materials. This imbalance between booming demand and limited supply bodes well for mining firms.

Additionally, the pandemic exposed risks of relying on a few countries for critical minerals. It revealed the need for domestic mining capacity to ensure stable access to essential inputs like lithium. For instance, the U.S. aims to boost domestic production of strategic minerals and reduce dependence on China. The EU also has a new plan to secure rare earth supplies within Europe. This focus on mineral independence is a plus for miners in North America and Europe.

Rising inflation and gold prices also bolster the case for mining stocks. With central banks printing huge amounts of money, many investors see gold as an inflation hedge. This has helped push gold prices to an 8-month high around $1900/ounce. Higher inflation tends to lift gold and silver prices as people flock to hard assets. Many miners produce both precious metals alongside base metals. They benefit from rising gold and silver prices.

Additionally, gold often rises when risks are high, like the current Russia-Ukraine and Israel-Gaza crises. Its safe haven appeal attracts buyers during geopolitical tensions. Between high inflation and geopolitical uncertainty, the macroeconomic environment seems favorable for both precious metal and base metal prices. This could kickstart a broad recovery across the mining sector.

The recent wave of mergers and acquisitions in mining also signals a positive shift. . In November 2023, Newmont Corporation completed its acquisition of Newcrest Mining Limited to create a leading global gold mining company with robust copper production. Just this month, Rio Tinto announced an $825 million lithium project purchase to support its battery materials business. These deals indicate big miners are positioning to capitalize on the electric vehicle revolution. Other companies like Century Lithium Corp. aim to produce lithium for the electric vehicle and battery storage market.

Additionally, mining stocks have held up well compared to the broader market’s decline. The global lithium stock index has surged over 110% in the past year. Many mining stocks linked to EVs have shown resilience amidst the tech stock plunge. This relative strength highlights the bullish outlook for miners enabling the energy transition. Noble Capital Markets’ investment banker Francisco Penafiel shared that “In the recent past, battery minerals have been getting the attention from investors, especially  critical metals such as lithium and cobalt. However, base metals like copper and nickel should also gain a healthy traction from the investment community, narrowing the existing valuation gap for junior miners,  due to the expected increase in their market demand as those are essential in the creation process of more efficient battery technologies”.   

After years of underperformance, mining stocks also look attractive relative to potential growth. For instance, the price-to-earnings ratio for diversified mining giant Glencore is under 6x, a bargain compared to high-flying tech stocks. While mining is volatile, long-term investors could be rewarded handsomely for their patience. The time seems ripe for mining stocks to revert upward after years of neglect.

Of course, risks exist like policy changes, permitting issues, cost inflation, and ESG concerns. But the overarching trend toward electrification seems unstoppable. While mining is cyclical, we appear to be entering an upcycle driven by underinvestment in new supply and exploding demand for the minerals needed to power the green transition.

Noble Capital Markets’ Senior Research Analyst, Mark Reichman states, “Our outlook for the mining sector remains favorable, particularly for the precious metals mining sub-sector. We believe growing electrification among developed nations and increased infrastructure spending bodes well for the long-term outlooks for metals such as copper, lithium, rare earths, and nickel. We think M&A activity will continue as large mining, energy, car manufacturers, and battery makers seek to de-risk their long-term strategies by ensuring long-term supplies of raw materials.”

In summary, mining stocks check many important boxes right now – strong demand drivers, favorable macro conditions, M&A activity, and reasonable valuations after a prolonged slump. The long-overlooked mining space seems poised for a renaissance, offering investors exciting opportunities. The winds appear to be shifting in favor of mining stocks as we embark on the new year and beyond. After years stuck in the doldrums, mining finally looks set to retake the spotlight.

Take a moment to take a look at Haynes International, a leading developer, manufacturer, and marketer of technologically advanced, nickel and cobalt-based high-performance alloys.

Alphabet Ends Relationship with AI Training Firm Appen in Major Blow

Posted on by slightbourne@noblecapitalmarkets.com

Tech giant Alphabet has decided to terminate its contractual relationship with Appen, an Australian company that has helped train many of Alphabet’s artificial intelligence products including the AI chatbot Bard.

Appen announced over the weekend that Alphabet notified them it will end all contracts effective March 19th. This is a massive blow to Appen, as Alphabet business accounts for around one-third of its total revenue.

Appen specializes in providing training data to tech firms to improve AI systems. It has helped train AI models for Microsoft, Apple, Meta, Amazon, Nvidia and others in addition to Alphabet. But the loss of the Alphabet contracts removes a huge chunk of its business.

Appen said it had no prior knowledge that Alphabet would end the relationship. The decision will impact thousands of subcontractors that Appen uses to source training data for Alphabet projects.

This termination caps what has been a very difficult stretch for the nearly 30-year-old Appen. The company has lost numerous major customers over the past two years as revenue declined 30% in 2023 and 13% in 2022.

Appen’s share price has also absolutely collapsed after peaking in 2020, falling over 99% from its high. Alphabet’s decision now deals a devastating blow to Appen’s attempts to turnaround the business.

Struggles Pivoting to Generative AI

Much of Appen’s struggles relate to challenges pivoting its offering to the new paradigm of generative AI. Models like ChatGPT and Google’s Bard work very differently than earlier AI systems. They rely more on processing power and less on human-labeled training data.

Former Appen employees said the company’s disjointed organizational structure and lack of quality control has hurt its ability to adapt its data services for generative AI. Appen touted work on search, translations, lidar, and more but large language models operate on a different scale.

For years Appen delivered solid growth supplying training data to Big Tech firms. But its business wasn’t built for the paradigm shift towards generative AI. Companies are spending far more on powerful AI chips from Nvidia and less on data from Appen.

Conflicts with Google

Interestingly, Appen has had public conflicts in the past with its now former major customer Alphabet. In 2019, Google mandated that contractors would have to pay workers at least $15 per hour. Appen did not meet that baseline wage requirement according to letters from some of its workers.

Earlier this year wage increases finally went into effect for Appen contractors working on Google projects like Bard. But other labor issues persisted. In June, Appen faced charges after allegedly firing six workers who spoke out about workplace frustrations.

This history of conflicts, along with Appen’s struggles to adapt to new AI needs, likely contributed to Alphabet’s decision to fully cut ties. The exact rationale remains unclear but the termination speaks to a relationship that was on shaky ground.

What’s Next for Appen

The loss of its Alphabet business leaves Appen in an extremely challenging position. In its filing, Appen said it will focus on managing costs and delivering quality AI training data to customers. But it has lost major customer after major customer in recent years.

Appen noted it will provide more details when it reports full year 2023 results in late February. But make no mistake, this termination represents a huge setback for its turnaround efforts.

For Alphabet, the move enables it to take greater control over how it sources training data and labeling for its AI systems. Relying less on third-party vendors aligns with its plans to invest heavily in developing its internal AI capabilities.

Meanwhile, the saga illustrates the rapid evolutions occurring in the AI sector. Generative models are transforming the field. For legacy players like Appen, adapting to stay relevant is proving enormously difficult.

Release – Bitcoin Depot Places Order for 500 New BTM Kiosks from Kiosk Provider Genmega

Posted on by aweinsoff@channelchek.com

Research New and Market Data on BTM

 

January 22, 2024 10:40 AM EST

BTM Acquisition Will Support the Company’s Bold Expansion Strategy as North America’s Market Share Leader

ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) — Bitcoin Depot (“Bitcoin Depot” or the “Company”) (NASDAQ: BTM), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, today announced the purchase order of 500 new Bitcoin ATM kiosks from Genmega, a leading manufacturer and provider of ATM and Kiosk solutions with well over 150,000 units deployed worldwide. The Company plans to strategically deploy these units as part of its ongoing expansion efforts throughout 2024 and beyond.

“The purchase order for these kiosks is significant as it demonstrates our ongoing commitment to a bold, strategic, and measured expansion this year,” said Bitcoin Depot CEO Brandon Mintz. “We are deeply committed to delivering a seamless and dependable experience to our retail partners and end users with a convenient experience through our kiosks. Genmega’s products have a proven track record of success, making them the ideal partner to reach new customers in 2024. We look forward to deploying these BTMs quickly in several key markets, as we continue championing widespread Bitcoin accessibility.”

Bitcoin Depot’s products and services provide an intuitive, quick, and convenient process for converting cash into Bitcoin, giving users the ability to access the broader, digital financial system, including using their Bitcoin for purposes of making payments, transfers, remittances, online purchases, and investments.

This news comes as the latest show of momentum for the Company following a string of recent expansion announcements and operational developments. In early 2022, Bitcoin Depot took over the #1 market share position to become the largest BTM operator in North America, and in 2023 – despite the turbulent cryptocurrency market – it became the first BTM operator to go public on a major U.S. stock exchange. Bitcoin Depot and its leadership have since been recognized and celebrated for the Company’s industry-leading growth in Forbes 30 Under 30, Deloitte’s 2023 Technology Fast 500, and, most recently, the 2023 Inc. 5000.

About Bitcoin Depot 
Bitcoin Depot Inc. (Nasdaq: BTM) was founded in 2016 with the mission to connect those who prefer to use cash to the broader, digital financial system. Bitcoin Depot provides its users with simple, efficient and intuitive means of converting cash into Bitcoin, which users can deploy in the payments, spending and investing space. Users can convert cash to bitcoin at Bitcoin Depot kiosks in 48 states and at thousands of name-brand retail locations in 29 states through its BDCheckout product. The Company has the largest market share in North America with approximately 6,400 kiosk locations as of September 30, 2023. Learn more at www.bitcoindepot.com 

Contacts: 

Investors  
Cody Slach, Alex Kovtun  
Gateway Group, Inc.  
949-574-3860  
BTM@gateway-grp.com 

Media  
Christina Lockwood, Brenlyn Motlagh, Ryan Deloney  
Gateway Group, Inc. 
949-574-3860  
BTM@gateway-grp.com 

Source: Bitcoin Depot Inc.

Released January 22, 2024

Noble Capital Markets Virtual Conferences

Posted on by cpatches

The Emerging Growth Virtual Basic Industries Conference – September 25-26, 2024

Set to be an immersive experience, bringing together investors, industry leaders, and experts in the natural resources, energy, industrials, and transportation sectors. Featuring:

Corporate presentations with Fireside-style Q&A session proctored by Noble’s analysts and bankers

Scheduled 1×1 meetings with qualified investors

Panel presentations led by key opinion leaders in the space

Why Present?

Noble’s investor base extends beyond traditional institutions to include family offices, money managers, and high-net-worth individuals who actively engage in smaller cap, open market transactions.

Noble’s investors crave the undervalued investment idea.

And not just investors that attend the live event. Channelchek will host replays of the corporate presentations and Q&A sessions right here, for all investors to view, free of charge, for the rest of the year.

Participation in conferences, both in-person and virtually, has proven to help in boosting awareness and liquidity. And Noble’s service offerings extend well beyond the conference circuit; our events are an extension of the year-round investor access we provide.

Ready to Register? Click the link below:

Register to Present – Virtual Basic Industries Equity Conference

Have questions about registering to present?

Email: Barbara Cohen

Learn more about Noble’s Investor Events throughout the year:

Noble Capital Markets Investor Events

Sunoco’s Blockbuster $7.3B Acquisition of NuStar to Reshape Energy Landscape

Posted on by slightbourne@noblecapitalmarkets.com

The energy sector experienced a major shakeup today as Sunoco LP announced it will acquire NuStar Energy in an all-stock deal valued at approximately $7.3 billion including debt. The blockbuster acquisition aims to create a more diversified and vertically integrated energy company with an expanded footprint across the value chain.

For Sunoco, the deal provides a number of key benefits that will strengthen its operations and financial position. Most notably, it will gain NuStar’s extensive pipeline and storage terminal network which spans over 9,500 miles across the United States. This will provide greater scale and diversification to Sunoco’s current focus on fuel distribution and retail. As pipeline assets generate steady contracted revenues, the acquisition is expected to add stability and predictability to cash flows.

The larger cash flow base will also improve Sunoco’s credit profile and enhance its financial flexibility. This will enable accelerated deleveraging while also supporting steady distribution growth. Management estimates the deal will be immediately accretive to distributable cash flow per unit by 10%+ within three years. Ongoing synergies of $150 million annually will also boost the bottom line.

Vertically integrating NuStar’s transportation and storage activities with Sunoco’s strengths in distribution and retail is another major strategic benefit. This will help optimize operations across the integrated value chain and lead to further efficiency gains over time. Cost savings are forecasted at $50 million per year.

For the energy sector overall, the deal also has important implications. The combined entity will control critical infrastructure delivering refined products across the United States. With its expanded footprint, Sunoco will play an even more pivotal role ensuring energy supplies are reliably transported to end-users nationwide.

The acquisition also arrives at a challenging time for the industry. Many energy companies are facing pressure from the transition towards renewable power. By combining forces, Sunoco and NuStar can cut costs, leverage their size and scale, and invest in new growth opportunities. This will ultimately strengthen their competitiveness and staying power.

However, the deal does raise some regulatory concerns. With its extensive control over pipelines and storage capacity, the merged company could potentially restrict competitors’ access. Watchdogs will want to ensure open access at fair rates. Still, management emphasized the acquisition will have a positive financial outlook and support continued distribution growth. This should benefit both sets of unitholders if the deal is approved as expected.

Looking ahead, the acquisition positions Sunoco and NuStar to play a pivotal role in the future of US energy infrastructure. Their integrated network will be crucial for delivering traditional and renewable fuels as the industry evolves. With enhanced financial strength and flexibility, the combined giants now have greater capacity to adapt and seize new opportunities in the years ahead.

Take a look at Noble Capital Markets’ Senior Research Analyst Michael Heim’s coverage universe to take a look at some emerging growth energy companies.

Release – Comtech Announces $45 Million Strategic Investment and Exchange of Convertible Preferred Stock

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CMTL

BY THE COMTECH EDITORIAL TEAM – JAN 22, 2024 | 4 MIN READ

Investment Enhances Comtech’s Financial Flexibility and Supports Its Strategic Initiatives in Satellite Ground Station Infrastructure and Next-Generation Terrestrial and Wireless Solutions

MELVILLE, N.Y. – January 22, 2024 — Comtech Telecommunications Corp. (NASDAQ: CMTL) (“Comtech” or the “Company”), a leading global technology company providing terrestrial and wireless network solutions, next-generation 911 emergency services, satellite and space communications technologies, and cloud native capabilities, today announced a $45.0 million investment by current shareholders White Hat Capital Partners LP (“White Hat”), an investment firm focused on sustainable value creation in technology companies serving mission-critical applications, and funds affiliated with Magnetar, a leading alternative investment manager with over $14 billion of assets under management. In connection with the investment, the Company exchanged all outstanding shares of Comtech’s existing convertible preferred stock for a new series of convertible preferred stock.

This strategic investment enhances Comtech’s financial flexibility and strengthens the Company’s ability to capitalize on its recent large contract awards and growing customer demand for its satellite communications technologies and next-generation terrestrial and wireless solutions. Comtech expects to apply the proceeds of this investment across a range of initiatives which not only support near-term working capital needs and general corporate purposes, including the repayment of certain outstanding indebtedness, but also its growth prospects. The issuance of the new series of convertible preferred stock demonstrates the continued commitment of White Hat and Magnetar, and is an important step towards the completion of the Company’s previously announced process to refinance its existing Credit Facility and further increase its financial and operational strength.

Mark Quinlan, who currently serves as an appointee of White Hat and Magnetar on the Company’s Board of Directors, will retain his position on the Board. Mr. Quinlan is White Hat’s Co-Founder and Managing Partner and has more than 20 years of experience in the technology sector. He has provided valuable insight and experience to the Board of Directors since January 2022.

“We are grateful for this investment and endorsement of our strategy and team by two of our existing long-term shareholders,” said Comtech’s Chairman and CEO, Ken Peterman. “Magnetar and White Hat understand our Company, our end markets, and the potential of our One Comtech vision. With White Hat’s investment experience within the technology sector and Magnetar’s breadth of investment experience in both private and public markets and across asset classes and capital structures, we value their continued support and are excited to strengthen our relationship with them at this key inflection point for the Company.”

“Under CEO Ken Peterman’s leadership, the entire Comtech team has made incredible progress on its One Comtech transformation,” said Mr. Quinlan. “We recognize Comtech’s potential and believe this investment further supports the Company’s commitment to developing and delivering mission-critical solutions for its customers.”

Summary of Investment Terms

White Hat and Magnetar purchased $45.0 million of a new series of convertible preferred stock and exchanged all outstanding shares of Comtech’s existing convertible preferred stock for shares of the new series of convertible preferred stock. The preferred stock will be convertible into shares of Comtech common stock at a conversion price of $7.99 per share; carries a 9.00% dividend, payable in kind, or a 7.75% dividend, payable in cash, at Comtech’s election; and contains an optional redemption date of October 31, 2028. Further details will be included in the Company’s Current Report on Form 8-K to be filed with the Securities and Exchange Commission. That report will describe the investment in additional detail, including exhibits with copies of associated transaction documentation.

Paul, Weiss, Rifkind, Wharton & Garrison LLP is serving as legal advisor to Comtech and Sidley Austin LLP is serving as legal advisor to the Special Committee of the Board of Directors of Comtech. Willkie Farr & Gallagher LLP is serving as legal advisor to Magnetar and Schulte Roth + Zabel LLP is serving as legal advisor to White Hat.

About Comtech

Comtech Telecommunications Corp. is a leading global technology company providing terrestrial and wireless network solutions, next-generation 9-1-1 emergency services, satellite and space communications technologies, and cloud native capabilities to commercial and government customers around the world. Comtech’s unique culture of innovation and employee empowerment unleashes a relentless passion for customer success. With multiple facilities located in technology corridors throughout the United States and around the world, Comtech leverages its global presence, technology leadership, and decades of experience to create the world’s most innovative communications solutions. For more information, please visit www.comtech.com.

Forward-Looking Statements

This press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties, including with respect to the offering of securities, the intended use of proceeds and our current expectations, initiatives, strategies or future plans. No assurance can be given that the transaction will be completed, or that the proceeds from the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, risks, and uncertainties, many of which are beyond the control of the Company, including those identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements are also based on assumptions that may not be realized and involve risks and uncertainties that could cause actual results or other events to differ materially from the expectations and beliefs contained herein. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in Securities and Exchange Commission filings. The Company undertakes no obligation to release publicly any updates or revisions to any forward-looking statements contained herein except as required by law.

PCMTL

View source version on businesswire.com: https://www.businesswire.com/news/home/20240122671989/en/

Investor Relations

Maria Ceriello

Investors@comtech.com

Release – DLH to Announce Fiscal 2024 First Quarter Financial Results

Posted on by aweinsoff@channelchek.com

Research News and Market Data on DLH

January 22, 2024

ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and human services provider to the federal government, will release financial results for the fiscal first quarter ended December 31, 2023 on January 31, 2024 after the market closes. DLH will then host a conference call for the investment community at 10:00 a.m. Eastern Time the following day, February 1, 2024, during which members of senior management will make a brief presentation focused on the financial results and operating trends. A question-and-answer session will follow. 

Interested parties may listen to the conference call by dialing 888-347-5290 or 412-317-5256.  Presentation materials will also be posted on the Investor Relations section of the DLH website prior to the commencement of the conference call. A digital recording of the conference call will be available for replay two hours after the completion of the call and can be accessed on the DLH Investor Relations website or by dialing 877-344-7529 and entering the conference ID 1843140.
  
About DLH
DLH (NASDAQ: DLHC) enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by federal customers, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 3,200 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to innovative solutions to improve the lives of millions. For more information, visit www.DLHcorp.com.

INVESTOR RELATIONS
Contact: Chris Witty
Phone: 646-438-9385
Email: cwitty@darrowir.com

Release – QuantaSing Announces Appointment of New Independent Director

Posted on by aweinsoff@channelchek.com

Research News and Market Data on QSG

January 22, 2024

BEIJING, Jan. 22, 2024 (GLOBE NEWSWIRE) — QuantaSing Group Limited (Nasdaq: QSG) (“QuantaSing” or the “Company”), today announced the appointment of a new independent director and a change to the audit committee of the Company’s board of directors (the “Audit Committee”).

Mr. Chenyang Wei was appointed as an independent director of the Company and as a member of the Audit Committee, effective on January 22, 2024.

Mr. Chenyang Wei has served as the Associate Dean of Institute for Fintech Research, Tsinghua University and Director of China Insurance and Pension Research Center, the National Institute of Financial Research, Tsinghua University PBC School of Finance since April 2019. From December 2016 to March 2019, Mr. Wei served as a senior managing director and chief U.S. economist in Zenity Asset Management Inc., a Silicon Valley-based asset management firm focusing on multi-sector asset allocation in the U.S. financial market. Prior to joining Zenity, Mr. Wei served as a director and head of credit research at AIG from August 2012 to December 2016. From June 2011 to August 2012, Mr. Wei was a senior economist with Federal Reserve Bank of Philadelphia. From 2006 to 2011, Mr. Wei was an economist with Federal Reserve Bank of New York. Mr. Wei is also an independent director of PICC Property and Casualty Company Limited (SEHK: 2328), HSBC Life Insurance Company Limited and Waterdrop Inc. (NYSE: WDH). He also served as an independent director of China Index Holdings Limited from May 2022 to April 2023. Mr. Wei received a bachelor’s degree in finance from Tsinghua University in 1996, a master’s degree in economics from McCombs School of Business, University of Texas at Austin in 2000, and a Ph.D. in finance from Leonard N. Stern School of Business, New York University in 2006.

Safe Harbor Statements

This announcement contains forward-looking statements within the meaning of Section 27A of Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended and the Private Securities Litigation Reform Act of 1955. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding QuantaSing’s financial outlook, beliefs and expectations. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets,” “guidance” and similar statements. Among other things, the Financial Outlook in this announcement contains forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases, and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s growth strategies; its future business development, results of operations and financial condition; its ability to attract and retain new users and learners and to increase the spending and revenues generated from users and learners; its ability to maintain and enhance the recognition and reputation of its brand; its expectations regarding demand for and market acceptance of its services and products; trends and competition in China’s adult learning market; changes in its revenues and certain cost or expense items; the expected growth of China’s adult learning market; PRC governmental policies and regulations relating to the Company’s business and industry, general economic and political conditions in China and globally, and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties, or factors is included in the Company’s filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

About QuantaSing Group Limited

QuantaSing is a leading online service provider in China dedicated to improving people’s quality of life and well-being by providing lifelong personal learning and development opportunities. The Company is the largest service provider in China’s online adult learning market and China’s adult personal interest learning market in terms of revenue, according to a report by Frost & Sullivan based on data from 2022. By leveraging its proprietary tools and technology, QuantaSing offers easy-to-understand, affordable, and accessible online courses to adult learners under a variety of brands, including QiNiu, JiangZhen and QianChi, empowering users to pursue personal development. Leveraging its extensive experience in individual online learning services, the Company has also expanded its services to corporate clients including, among others, marketing services and enterprise talent management services.

For more information, please visit: https://ir.quantasing.com.

Contact

Investor Relations
Leah Guo
QuantaSing Group Limited
Email: ir@quantasing.com
Tel: +86 (10) 6493-7857

Robin Yang, Partner
ICR, LLC
Email: QuantaSing.IR@icrinc.com
Phone: +1 (212) 537-0429

No Recession in Sight for 2024, Say Davos Attendees

Posted on by slightbourne@noblecapitalmarkets.com

The annual World Economic Forum concluded on Friday in Davos, Switzerland, after a week of insight from some of the biggest names in business and politics. One of the main takeaways was optimism about avoiding a recession in the U.S. this year, despite ongoing economic concerns.

Most experts and executives see steady growth continuing in 2024, believing the economy remains on solid footing. Reasons for their confidence include potential interest rate cuts by the Federal Reserve in coming months, which could further stimulate economic activity. Consumer confidence has also been rising, suggesting households are eager to keep spending. Barring any major global crises, these factors have led to consensus that a downturn is unlikely in the next year.

The optimism comes as a breath of fresh air after massive disruption from the pandemic in recent years. However, other parts of the world are facing greater struggles. China in particular is dealing with slower growth, which prompted officials to reveal at Davos that their GDP expanded by just 5.2% in 2023. That’s down significantly from the 6-7% range China was averaging pre-pandemic.

Reasons for the slowdown include an ongoing semiconductor trade battle with the U.S. that is hurting tech manufacturing. China is also losing foreign direct investment as companies eye other Asian markets with friendlier business climates. The country recently lost its spot as the world’s most populous to rival India as well. With these challenges mounting, China appears eager for overseas capital to help spur its economy. Its officials breaking precedent to announce 2023 GDP numbers hints at this thirst for foreign money.

While China scrambles, Davos remains as popular as ever, albeit with some growing pains. Several regular attendees commented that the city is having infrastructure troubles keeping up with swarming conferences like the World Economic Forum. Traffic jams of shuttles and Ubers have become constant as hotels fill up. Local government officials apparently can’t even expense rooms anymore due to astronomical prices driven by demand.

This disruption didn’t stop high-level conversations on major themes like technology and geopolitics. Artificial intelligence was one of the hottest topics this year, taking over from the crypto hype of 2022. Companies flooded Davos with advertisements for their AI products and services. Headliners like will.i.am spoke enthusiastically about AI’s potential, announcing plans for a new podcast co-hosted with an AI companion.

But among the boosterism were voices urging calm and perspective. Sam Altman of OpenAI said AI will “change the world much less than we all think.” He noted how companies are using AI as a collaborative tool alongside human employees, rather than replacing them outright. Such measured takes may ease fears about mass job losses from automation. Job postings remain high in most countries, signaling an ongoing need for human skills and oversight.

While AI took center stage this year, some pressing geopolitical matters received surprisingly little airtime. The conflict between Israel and Hamas was rarely discussed, despite its global significance. Some speculate that businesses are wary of irritating stakeholders by speaking out on the polarizing topic. Similar logic may be why few executives criticized the prospect of Donald Trump returning to power. Staying cautiously neutral, however cynical, remains the safest option for profits.

Relatedly, the rise in antisemitism worldwide was a glaring omission in Davos discussions per some attendees. Finding constructive ways to combat prejudice could have been a valuable session. But the lack of debate on this and other divisive issues speaks to a gathering that ultimately caters to the global elite.

AI and recession talk make for good business panel chatter, but taking on discrimination may be beyond Davos’s comfort zone. As the conference’s popularity increases however, pressure may mount to address the most vital social issues of the day rather than sidestep them. Navigating that tension will be key to keeping Davos a premiere gathering of thought leaders.

For now, the World Economic Forum remains sold out and buzzing. Its reputation seems secure even as conversations gravitate toward the safest corporate ground. But avoiding the divides splintering society risks making Davos an echo chamber detached from reality. If it wants to keep its relevance, future forums may need to push attendees out of their comfort zones.